Anticancer Effect of Hemin through ANO1 Inhibition in Human Prostate Cancer Cells
International Journal of Molecular Sciences · 30.05.2024 · 25 (11) · 6032
DOI: 10.3390/ijms25116032 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 30.05.2024. Verfasst von So-Hyeon Park und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy and Yonsei Institute of Pharmaceutical Sciences, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Kor…. Hauptthemen laut MEDLINE: Anoctamin-1, Antineoplastic Agents, Hemin, Neoplasm Proteins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Basic Science Research Program through the National Research Foundation of Korea (NRF), Ministry of Education.
Abstract (Originalsprache)
Anoctamin1 (ANO1), a calcium-activated chloride channel, is overexpressed in a variety of cancer cells, including prostate cancer, and is involved in cancer cell proliferation, migration, and invasion. Inhibition of ANO1 in these cancer cells exhibits anticancer effects. In this study, we conducted a screening to identify novel ANO1 inhibitors with anticancer effects using PC-3 human prostate carcinoma cells. Screening of 2978 approved and investigational drugs revealed that hemin is a novel ANO1 inhibitor with an IC50 value of 0.45 μM. Notably, hemin had no significant effect on intracellular calcium signaling and cystic fibrosis transmembrane conductance regulator (CFTR), a cyclic AMP (cAMP)-regulated chloride channel, and it showed a weak inhibitory effect on ANO2 at 3 μM, a concentration that completely inhibits ANO1. Interestingly, hemin also significantly decreased ANO1 protein levels and strongly inhibited the cell proliferation and migration of PC-3 cells in an ANO1-dependent manner. Furthermore, it strongly induced caspase-3 activation, PARP degradation, and apoptosis in PC-3 cells. These findings suggest that hemin possesses anticancer properties via ANO1 inhibition and could be considered for development as a novel treatment for prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy and Yonsei Institute of Pharmaceutical Sciences, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Korea.
- Graduate Program of Industrial Pharmaceutical Science, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Korea.
ORCID-Profile: So-Hyeon Park, Yechan Lee, Hyejin Jeon, Wan Namkung
Förderung
- National Research Foundation of Korea
- Basic Science Research Program through the National Research Foundation of Korea (NRF)
- Ministry of Education
Zitieren
APA
Park, S. H., Lee, Y., Jeon, H., Park, J., Kim, J., Kang, M., & Namkung, W. (2024). Anticancer Effect of Hemin through ANO1 Inhibition in Human Prostate Cancer Cells. International Journal of Molecular Sciences, 25(11), 6032. https://doi.org/10.3390/ijms25116032
Vancouver
Park SH, Lee Y, Jeon H, Park J, Kim J, Kang M, et al. Anticancer Effect of Hemin through ANO1 Inhibition in Human Prostate Cancer Cells. International Journal of Molecular Sciences. 2024;25(11):6032. doi:10.3390/ijms25116032
BibTeX
@article{Park2024,
author = {Park, So-Hyeon and Lee, Yechan and Jeon, Hyejin and Park, Junghwan and Kim, Jieun and Kang, Mincheol and Namkung, Wan},
title = {Anticancer Effect of Hemin through ANO1 Inhibition in Human Prostate Cancer Cells},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {11},
pages = {6032},
doi = {10.3390/ijms25116032}
}
EUVIMED